B. Braun Partners with Cognite to Power Its Data-First Transformation
17.1.2023 10:00:00 EET | Business Wire | Press release
Cognite, a global leader in industrial software, today announced B. Braun, a leading medical technology company, has selected Cognite Data Fusion® as the core of its Manufacturing Data Management solution. By integrating Cognite’s Industrial DataOps platform with its manufacturing domain knowledge, B. Braun leverages digital twins and AI-powered applications to achieve operational excellence across production, maintenance, and sustainability.
The Manufacturing Data Management solution will provide a fully digital DevOps workflow to develop, deploy, and sustain a pipeline of business applications. Cognite Data Fusion® will integrate and contextualize all operational data from product development, engineering, production, quality management, maintenance, EHS, and enterprise systems into one contextualized data layer that adheres to and extends industry standards for data modeling and enables the evolution of those data models over time as needed. The Manufacturing Data Management solution will provide comprehensive, easily accessible, and trusted information to both domain experts and developers, creating the foundation for data-driven transformation at scale.
Abram Ziegelaar, VP of Operational Technology at B. Braun Medical Industries in Malaysia, highlights three main value drivers of the solution:
"First, our wide variety of front-line workers and domain experts can collaborate with a common pool of trusted, real-world, live data from diverse sources and integrated, standardized applications. They get the information they need with the business context they need to respond quickly. This provides significant efficiency gains and reduces errors caused by poor quality or inaccessible information and disjointed processes.
" Second, our front-line people often intuitively know what needs to be done to improve performance, but lack the tools to test their intuition. Controlled access to a rich universe of well-curated information turns our front-liners into 'citizen data scientists' who can own their reports and analyses, make better decisions, and demonstrate the viability of improvement possibilities with real data. After implementation, we can measure the actual effects of improvements. Doing all of this in a global platform across many sites allows us to rapidly spread this knowledge and multiply the gains. 'Continuous Improvement' really becomes continuous.
" Third, you don't know what you don't know. A unique value of Cognite Data Fusion's AI-powered data contextualization is how it provides us with the 'smarts’ to answer very complex questions and create visibility into new areas to explore."
"On behalf of Cognite, we are proud to partner with B. Braun as they transform into a data-first organization based on a strong operational data foundation. Cognite Data Fusion®, which provides simple access to complex industrial data, will fast track time to value of the Manufacturing Data Management solution and empower B. Braun to build and scale valuable business solutions," said Petteri Vainikka, Chief Marketing Officer at Cognite.
As part of the partnership, Cognite will collaborate with B. Braun to integrate its in-house support tools with Cognite’s user community, Cognite Hub, to provide seamless support to the B. Braun organization. To learn more about Cognite Data Fusion, visit: cognite.com/en/product/cognite_data_fusion_industrial_dataops_platform
About B. Braun
As one of the world's leading medical technology companies, B. Braun protects and improves the health of people around the world. For over 180 years, the family-owned company has been accelerating progress in health care with pioneering spirit and groundbreaking contributions. This innovative strength continues to be the foundation of B. Braun's success today—always with the goal of improving clinical outcomes, cost of care, and patient benefits.
More than 66,000 employees live Sharing Expertise worldwide, they make B. Braun a true partner that develops smart solutions and sets new standards. By linking products, services, and consulting, the company improves treatment processes and supports medical staff. In doing so, B. Braun always acts with future generations in mind, which is why responsibility for sustainable growth is embedded into all business processes. In 2021, the B. Braun Group generated sales of € 7.9 billion. Visit us at www.bbraun.com.
About Cognite
Cognite is a global industrial SaaS company that was established with a clear vision: to rapidly empower industrial companies with open, contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-intensive industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005369/en/
Contact information
Michelle Holford, Vice President of Global Public Relations
michelle.holford@cognite.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release
Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are
Andersen Consulting Broadens Data and Analytics Capabilities with Insight Consulting18.2.2026 16:30:00 EET | Press release
Andersen Consulting adds depth to its platform through a Collaboration Agreement with Insight Consulting, a leading data and digital strategy consultancy with a presence in South Africa, Mozambique, and the UK. Insight Consulting provides end-to-end services across the digital value network, including digital strategy, digital fluency, enterprise AI, custom software development, data integration, analytics, and planning and forecasting. Its multidisciplinary teams bring expertise in people, technology, and process, ensuring that effective change management encompasses all three of these elements. The firm works across industries such as retail, logistics, hospitality, finance, manufacturing, travel, agriculture, automotive, and healthcare. “Collaborating with Andersen Consulting gives us access to a wider global footprint and advanced methodologies, while also allowing us to contribute our regional knowledge and expertise in data and analytics,” said Sean Taylor, director of Insight Co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
